Skip to main content
TipRanks
Go Ultimate75% OFF

Invion (IVIXF) AI Stock Analysis

37 Followers
IVIXF

Invion

(Other OTC:IVIXF)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Proprietary therapy platformA proprietary Photosoftâ„¢ platform gives Invion a defined technological base for developing photodynamic cancer treatments. Its light-activated approach is intended to selectively destroy cancer cells and may also stimulate anti-tumour immune responses, creating potential differentiation if clinical development succeeds.
Negative Factors
Persistent unprofitabilityRecurring operating and net losses show that Invion has not yet converted its research activities into a profitable operating model. Continued losses can consume capital, restrict investment in clinical development, and make future financial performance dependent on achieving successful commercialization or securing additional funding.

Invion (IVIXF) vs. SPDR S&P 500 ETF (SPY)

-5%0%5%10%15%20%IVIXF0.00%SPY+14.55%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
$4.08M
Dividend Yield
―
Average Volume (3M)
―
Price to Earnings (P/E)
-0.5
Beta (1Y)
-3.38
Revenue Growth
―
EPS Growth
46.36%
Country
US
Employees
8
Sector
Healthcare
Sector Strength
51
Industry
Drug Manufacturers - Specialty & Generic

Invion Business Overview & Revenue Model

Company Description

Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being...

Invion Peers Comparison

Overall Rating

UnderperformOutperform
Sector (51)

Financial Indicators

IVIXF against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
AU:MVPAU:MVP57NeutralAUD 48.44M76.781.13%―8.99%450.00%
Sector *51Neutral$7.86B-0.30-43.30%2.27%22.53%-2.21%
AU:PERAU:PER45NeutralAUD 6.94M-0.73-65.33%――72.60%
AU:PKPAU:PKP39UnderperformAUD 18.75M-5.074388.00%―-19.73%50.34%
AU:RGTAU:RGT37UnderperformAUD 2.48M-0.20102.60%―17.56%75.11%
AU:IDTAU:IDT34UnderperformAUD 14.06M-5.31-13.81%―5.93%66.32%

* Healthcare Sector Average

Performance Comparison

-60%-40%-20%0%IVIXFAU:RGTAU:MVPAU:PKPAU:IDTDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IVIXF and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IVIXFInvion Ltd.0.040.000.00%
AU:PERPercheron Therapeutics Limited―――
AU:RGTArgent Biopharma Ltd0.02-0.06-74.39%
AU:MVPMedical Developments International Limited0.43-0.13-23.21%
AU:PKPAlthea Group Holdings Ltd.0.01-0.01-30.00%
AU:IDTIDT Australia Limited0.03-0.02-41.38%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.